| Name | Title | Contact Details |
|---|
Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.
NICO gives hope to patients with primary and secondary brain tumors, cysts and hemorrhagic strokes.
Odyssey Research Services is a Bismarck, ND-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioHarp UNI US is a Sun Valley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Pearl Therapeutics is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.